Department of Psychiatry, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of psychiatry, Taleghani Hospital Research Development Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
J Addict Dis. 2021 Jul-Sep;39(3):357-362. doi: 10.1080/10550887.2021.1886566. Epub 2021 Mar 6.
Investigations proposed that genetic polymorphisms within proteins in methadone pharmacokinetic and pharmacodynamics are critical factors in determination of methadone dose in methadone maintenance therapy (MMT).
This study aimed to assess the associations between two polymorphisms, (rs2740574) and (rs1799971), with dose of methadone in Iranian patients undergoing MMT.
A total of 124 Iranian male subjects aged 18-65 years old who were confirmed to be addicted by the addiction diagnostic tests and underwent MMT were assessed. Patients were divided into three groups of low (less than 40 mg/day), moderate (more than 40 mg/day and less than 110 mg/day) and high (more than 110 mg/day) methadone dose consumption. DNAs of included patients were extracted from their blood samples and were assessed for and polymorphisms.
Results showed that there was no significant association between the studied polymorphisms and methadone dose in Iranian addicted patients underwent MMT (P > 0.05).
and single variations cannot explain variability in methadone dosage in MMT. Studying the interactions of more genetic factors in larger samples may elucidate factors influencing the required dose of methadone and better individualized therapy.
研究表明，美沙酮药代动力学和药效学蛋白内的遗传多态性是决定美沙酮维持治疗（MMT）中美沙酮剂量的关键因素。
本研究旨在评估两个单核苷酸多态性（rs2740574 和 rs1799971）与伊朗 MMT 患者美沙酮剂量之间的关联。
共评估了 124 名年龄在 18-65 岁之间的伊朗男性患者，这些患者通过成瘾诊断测试被确认为成瘾者，并接受了 MMT。患者被分为三组：低剂量组（<40mg/天）、中剂量组（>40mg/天且<110mg/天）和高剂量组（>110mg/天）。从患者的血液样本中提取 DNA，评估 和 多态性。
结果显示，在所研究的多态性与接受 MMT 的伊朗成瘾患者的美沙酮剂量之间没有显著关联（P>0.05）。
单独的变异不能解释 MMT 中美沙酮剂量的可变性。在更大的样本中研究更多遗传因素的相互作用，可能会阐明影响美沙酮所需剂量的因素，并实现更好的个体化治疗。
